Ionis announces European Medicines Agency accepts Marketing Authorization Application of tofersen to treat rare, genetic form of ALS

SOD1-ALS affects approximately 2% of people living with ALS worldwide1 If approved, tofersen would be the world’s first treatment to target a genetic cause of ALS EMA acceptance follows FDA’s acceptance of tofersen NDA earlier this year CARLSBAD, Calif., Dec. 5, 2022 /PRNewswire/ — Ionis…

Click here to view original post